This company listing is no longer active
Annexin Pharmaceuticals Management
Management criteria checks 1/4
Annexin Pharmaceuticals' CEO is Anders Haegerstrand, appointed in Oct 2019, has a tenure of 4.67 years. directly owns 0.28% of the company’s shares, worth SEK445.22K. The average tenure of the management team and the board of directors is 3.2 years and 0.9 years respectively.
Key information
Anders Haegerstrand
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.2yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO
Anders Haegerstrand (63 yo)
4.7yrs
Tenure
Dr. Anders Haegerstrand, M.D. Ph.D. is Chief Executive Officer at Annexin Pharmaceuticals AB (publ) since October 2019. He served as Director at Annexin Pharmaceuticals AB since 2018 until 2020. He served...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.7yrs | no data | 0.28% SEK 445.2k | |
| Chief Financial Officer | 1.2yrs | no data | no data | |
| Chief Operating Officer | 6.4yrs | no data | 0.055% SEK 85.7k | |
| Chief Scientific & Medical Officer | 8.4yrs | no data | no data | |
| Head of CMC | 3.2yrs | no data | no data | |
| Therapeutic Area Head of Ophthalmology | 2.3yrs | no data | no data | |
| Head of Oncology of Therapy Area | 1.4yrs | no data | no data |
3.2yrs
Average Tenure
52.5yo
Average Age
Experienced Management: ANNX BTA's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board | less than a year | no data | no data | |
| Independent Director | 7.4yrs | no data | 0.18% SEK 289.3k | |
| Director | less than a year | no data | 25.89% SEK 40.6m | |
| Independent Director | 1.4yrs | no data | no data |
0.9yrs
Average Tenure
73yo
Average Age
Experienced Board: ANNX BTA's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.